News

Additional subjects are being evaluated for eligibility for entrance into the trial or are awaiting treatment at the two active centers in Brisbane and Sydney, Australia. In addition,

The FDA clearance to market was based upon data showing DR-70 (FDP) has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy

Light Sciences Oncology (LSO) plans to conduct a 12-patient, Phase I/II dose-escalation study at four sites in the US as well as a 40-patient, Phase IIa study in

With receipt of this license, the company has completed the acquisition of 63.3% of Shanghai Rongheng Pharmaceutical. Shanghai Rongheng International Trade of Orient International, CAS Shanghai Shenglongda Biotech

The in- vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes after injection with only minor retention in the liver and heart.

Previously, Dr Wotton served as CEO of Topigen Pharmaceuticals. Prior to joining Topigen, Dr Wotton served as head of global business development at SkyePharma. Dr Wotton has over

According to the company, the new version of the ClinQuick system includes a more user-friendly interface, improved menu navigation and a more robust data platform. This new platform

The transaction was completed substantially under the original terms announced on April 1, 2008, which called for Church & Dwight to pay $380 million in cash at closing.

Relistor subcutaneous injection is indicated for opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to the usual laxative therapy has not